Nanomaterials for the treatment and diagnosis of Alzheimer's disease: An overview
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Abstract Alzheimer's disease (AD) is a chronic neurodegenerative disorder associated with dementia. To overcome the limitations of diagnosis and treatment nanotechnology research is bringing more needed and optimum clinical results. The use of nanocarriers for delivering bio-actives to treat neurodegenerative diseases has shown many benefits over common therapies such as the possibility of loading various payloads, controllable delivery, and amenability to surface modification with target ligands that can promote the crossing of the blood-brain barrier (BBB) for efficient distribution of bioactive into the brain. This review spotlights the applications of nanocarriers such as magnetic nanoparticles, carbon nanotubes, quantum dots, polymeric nanocapsules, multifunctional nanoliposomes, and nanoemulsions in the treatment of neurodegenerative diseases. The production of biosensors for the identification of Alzheimer's disease biomarkers has made considerable progress due to advances in nanoscience. The special properties of nanomaterials (such as graphene, carbon nanotubes, silver, gold, magnetic nanoparticles, polymers, and quantum dots) can improve the optical and electrochemical behavior of transducers. Therefore, electrochemical and optical biosensors with better sensitivity, selectivity, and prolonged stability desired. After all, the methods that focused on the identification of multiple analytes should be strengthened to reduce misdiagnosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
The neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461
Glowing Graphene Quantum Dots and Carbon Dots: Properties, Syntheses, and Biological Applications
Zheng, X. T., Ananthanarayanan, A., Luo, K. Q., & Chen, P. (2015) · Small · doi:10.1002/smll.201402648 · Cited by 2,190
Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609
Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease
Bezprozvanny, I., & Mattson, M. P. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.005 · Cited by 938
Georganopoulou, D. G., Chang, L., Nam, J.-M., Thaxton, C. S., Mufson, E. J., Klein, W. L., & Mirkin, C. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409336102 · Cited by 835
Alzheimer's disease drug development pipeline: 2019
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.05.008 · Cited by 762
Cited by
Monteiro, A. R., Barbosa, D. J., Remião, F., & Silva, R. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115522 · Cited by 329
Enhancing autophagy in Alzheimer's disease through drug repositioning
Eshraghi, M., Ahmadi, M., Afshar, S., Lorzadeh, S., Adlimoghaddam, A., Rezvani Jalal, N., West, R., Dastghaib, S., Igder, S., Torshizi, S. R. N., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108171 · Cited by 89
La Barbera, L., Mauri, E., D’Amelio, M., & Gori, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.939855 · Cited by 74
Nanotechnology in the diagnostic and therapy for Alzheimer's disease
Panghal, A., & Flora, S. J. S. (2024) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2024.130559 · Cited by 31
Metadata
- Authors
- Bilal, M., Barani, M., Sabir, F., Rahdar, A., & Kyzas, G. Z.
- Venue
- NanoImpact
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 20
- Pages
- 100251
- ISSN
- 2452-0748 (ISSN-L)
- OpenAlex
- W3082682877
- Cited by
- 126
- References
- 22
- FWCI
- 9.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nanomaterials for the treatment and diagnosis of Alzheimer's disease: An overview. https://app.cochat.ai/papers/10.1016/j.impact.2020.100251
- The paper
- Bilal, M., Barani, M., Sabir, F., Rahdar, A., & Kyzas, G. Z. (2020). Nanomaterials for the treatment and diagnosis of Alzheimer's disease: An overview. NanoImpact. https://doi.org/10.1016/j.impact.2020.100251
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.